The First In Vivo CRISPR Therapy Could Be Approved by the FDA in 2027 – The Babak Lab
The Babak Lab/LinkedIn

The First In Vivo CRISPR Therapy Could Be Approved by the FDA in 2027 – The Babak Lab

The Babak Lab shared on LinkedIn:

“The first in vivo CRISPR therapy could be approved by the FDA in 2027

A recent Nature report discusses new four-year follow-up data for lonvoguran ziclumeran (lonvo-z, NTLA-2002), a CRISPR-based treatment for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent swelling attacks.

Unlike currently approved CRISPR treatments, lonvo-z edits genes directly inside the body through a single intravenous infusion.

Key Insights

  • Lonvo-z uses CRISPR-Cas9 to inactivate the KLKB1 gene in liver cells, reducing plasma kallikrein production.
  • In the Phase 3 HAELO trial (80 patients), treatment reduced monthly HAE attacks by 87% compared with placebo.
  • Phase 1/2 follow-up data showed sustained reductions in plasma kallikrein for up to four years after treatment.
  • The treatment uses lipid nanoparticles to deliver CRISPR components to liver cells, avoiding the need to remove and edit cells outside the body.
  • The FDA has granted Priority Review, with a decision expected by March 10, 2027.

Conclusion

The four-year follow-up provides evidence that a single dose of lonvo-z can produce lasting effects without repeated treatment.

If approved, it would become the first FDA-authorized in vivo CRISPR therapy. Long-term safety monitoring will remain important, particularly because gene editing inside the body does not allow edited cells to be screened before treatment.”

Title: New CRISPR therapy is poised to gain first FDA approval to alter genes inside the body

Authors: Heidi Ledford

Read the Full Article on Nature

You can also read: CRISPR in Cancer Immunotherapy and Precision Oncology

The First In Vivo CRISPR Therapy Could Be Approved by the FDA in 2027 - The Babak Lab